<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01213576</url>
  </required_header>
  <id_info>
    <org_study_id>FED-311207</org_study_id>
    <nct_id>NCT01213576</nct_id>
  </id_info>
  <brief_title>Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi</brief_title>
  <acronym>FED</acronym>
  <official_title>Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Albendazole and ivermectin are currently used in combination for annual mass treatment of
      lymphatic filariasis in Africa. Although the drugs have been donated, the cost of such
      programmes is very high and has proven to be a major impediment to the success of programmes
      in many countries with limited financial resources.

      Data from albendazole treatment of other filarial infections and one study comparing single
      to multi-dose Diethycarbamazine/albendazole in lymphatic filariasis suggest that increased
      dose and/or frequency of albendazole dosing may be more effective in clearing microfilariae.
      It is essential to determine whether such higher doses are indeed beneficial since this could
      have far-reaching effects on the conduct and management of the main mass treatment programmes
      and also in the management of programmes as they near elimination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will enrol up to 120 volunteers with microfilaremic Wuchereria bancrofti
      infection who would be randomized to receive standard annual treatment (albendazole 400 mg +
      ivermectin 200 mcg/kg), annual treatment with an increased dose of albendazole (albendazole
      800 mg + ivermectin 200400 mcg/kg) or semi-annual treatment with a standard (albendazole 400
      mg + ivermectin 200 mcg/kg), or an increased albendazole dose (albendazole 800 mg +
      ivermectin 200 400 mcg/kg). Microfilarial levels, as well as measures of adult worm burden
      (circulating antigen) will be followed every six months for two years to determine whether
      the higher doses, or more frequent regimens are more effective.

      The data obtained would be used, in combination with the data from other similar studies
      being conducted in Mali and in India to advise the Global Programme for the Elimination of
      Lymphatic Filariasis (GPELF) on improved methods of treatment both for mass treatment and for
      the management of problem areas within the global programme.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Introduction of National Mass Drug Administration Campaign and failure to identify appropriate
    participants.
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving Microfilarial Clearance</measure>
    <time_frame>12 months</time_frame>
    <description>Microfilaria clearance will be assessed in regard to dosage as well as frequency of treatment. Microfilarial clearance is defined by non-detection of microfilaria in the night blood sample.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Microfilarial Clearance at 24 Months of Follow up</measure>
    <time_frame>24 months</time_frame>
    <description>Microfilaria will be detected using the nucleopore filtration technique and analysed according to the respective treatment arms at the 24 month time point. Microfilarial clearance will be defined by non-detection of microfilaria in the night blood sample</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Lymphatic Filariasis</condition>
  <arm_group>
    <arm_group_label>albendazole 400mg and ivermectin 200mcg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Annual treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albendazole 800mg and ivermectin 400mcg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Annual treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albendazole 400mg and ivermectin 200mcg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>albendazole 400mg and ivermectin 200mcg/kg given twice a year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albendazole 800mg and ivermectin 400mcg /kg bi-annually</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Albendazole 800mg and ivermectin 400mcg/kg given twice a year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole 400mg and ivermectin 200mcg/kg</intervention_name>
    <description>400 mg orally given annually</description>
    <arm_group_label>albendazole 400mg and ivermectin 200mcg/kg</arm_group_label>
    <arm_group_label>Albendazole 400mg and ivermectin 200mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole and ivermectin</intervention_name>
    <description>albendazole 800 mg and ivermectin 400mg orally given annually</description>
    <arm_group_label>Albendazole 800mg and ivermectin 400mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole 400mg and ivermectin 200mcg/kg</intervention_name>
    <description>Albendazole 400mg and ivermectin 200mcg/kg given twice a year</description>
    <arm_group_label>albendazole 400mg and ivermectin 200mcg/kg</arm_group_label>
    <arm_group_label>Albendazole 400mg and ivermectin 200mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albendazole 800mg and ivermectin 400mcg/kg bi-annually</intervention_name>
    <description>albendazole 800mg and ivermectin 400mcg/kg given twice a year</description>
    <arm_group_label>Albendazole 800mg and ivermectin 400mcg /kg bi-annually</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  understand and sign informed consent

          -  willing to undergo night blood sampling every 6 months for 2 years

          -  Age 18 to 55 years

          -  Haemoglobin of equal or above 9g/dl

          -  Microfilarial level of equal or above 80mg/dl

        Exclusion Criteria:

          -  Non- consenting

          -  Pregnancy or lactation

          -  Treatment with albendazole or ivermectin within the previous 6 months

          -  Known allergy to the study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil French, MB ChB PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karonga Prevention Study</name>
      <address>
        <city>Karonga</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malawi</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <results_first_submitted>February 10, 2015</results_first_submitted>
  <results_first_submitted_qc>February 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2015</results_first_posted>
  <last_update_submitted>February 26, 2015</last_update_submitted>
  <last_update_submitted_qc>February 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>London School of Hygiene and Tropical Medicine</investigator_affiliation>
    <investigator_full_name>Neil French</investigator_full_name>
    <investigator_title>Reader In Infectious Disease Epidemiology/Director KPS</investigator_title>
  </responsible_party>
  <keyword>Lymphatic filariasis</keyword>
  <keyword>microfilaria</keyword>
  <keyword>Albendazole</keyword>
  <keyword>ivermectin</keyword>
  <keyword>human immunodeficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Filariasis</mesh_term>
    <mesh_term>Elephantiasis</mesh_term>
    <mesh_term>Elephantiasis, Filarial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Albendazole 400mg and Ivermectin 200mcg/kg Annually</title>
          <description>Once a year treatment
Albendazole 400mg and ivermectin 200mcg/kg: 400 mg oral</description>
        </group>
        <group group_id="P2">
          <title>Albendazole 800mg and Ivermectin 400mcg/kg Annually</title>
          <description>Once a year treatment
Albendazole and ivermectin: albendazole 800 mg and ivermectin 400mg oral</description>
        </group>
        <group group_id="P3">
          <title>Albendazole 400mg and Ivermectin 200mcg/kg Biannually</title>
          <description>Twice a year
albendazole 400mg and ivermectin 200mcg/kg given twice a year</description>
        </group>
        <group group_id="P4">
          <title>Albendazole 800mg and Ivermectin 400mcg /kg Bi-annually</title>
          <description>Twice a year
Albendazole 800mg and ivermectin 400mcg/kg given twice a year</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Albendazole 400mg and Ivermectin 200mcg/kg Annual</title>
          <description>Albendazole 400mg and ivermectin 200mcg/kg: 400 mg orally given once a year</description>
        </group>
        <group group_id="B2">
          <title>Albendazole 800mg and Ivermectin 400mcg/kg Annual</title>
          <description>Albendazole and ivermectin: albendazole 800 mg and ivermectin 400mg orally given once a year</description>
        </group>
        <group group_id="B3">
          <title>Albendazole 400mg and Ivermectin 200mcg/kg Biannual</title>
          <description>Albendazole 400mg and ivermectin 200mcg/kg given twice a year</description>
        </group>
        <group group_id="B4">
          <title>Albendazole 800mg and Ivermectin 400mcg/kg Bi-annual</title>
          <description>Albendazole 800mg and ivermectin 400mcg/kg given twice a year</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" lower_limit="21" upper_limit="50"/>
                    <measurement group_id="B2" value="31" lower_limit="20" upper_limit="53"/>
                    <measurement group_id="B3" value="27.5" lower_limit="18" upper_limit="55"/>
                    <measurement group_id="B4" value="35" lower_limit="20" upper_limit="54"/>
                    <measurement group_id="B5" value="33" lower_limit="18" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Malawi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Microfilarial count /uL</title>
          <units>microfilaria/uL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="464.7" lower_limit="250.1" upper_limit="863.4"/>
                    <measurement group_id="B2" value="338.7" lower_limit="198.7" upper_limit="577.4"/>
                    <measurement group_id="B3" value="204.5" lower_limit="204.5" upper_limit="287.8"/>
                    <measurement group_id="B4" value="264.7" lower_limit="175.0" upper_limit="400.4"/>
                    <measurement group_id="B5" value="298.6" lower_limit="207.3" upper_limit="389.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eosinophil count</title>
          <units>cells/uL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1300" lower_limit="1000" upper_limit="1700"/>
                    <measurement group_id="B2" value="1400" lower_limit="1000" upper_limit="1900"/>
                    <measurement group_id="B3" value="1600" lower_limit="1100" upper_limit="2100"/>
                    <measurement group_id="B4" value="1100" lower_limit="900" upper_limit="1500"/>
                    <measurement group_id="B5" value="1300" lower_limit="1000" upper_limit="1800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving Microfilarial Clearance</title>
        <description>Microfilaria clearance will be assessed in regard to dosage as well as frequency of treatment. Microfilarial clearance is defined by non-detection of microfilaria in the night blood sample.</description>
        <time_frame>12 months</time_frame>
        <population>Number of participants with non detectable microfilaria at follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Albendazole 400mg and Ivermectin 200mcg/kg Annually</title>
            <description>Once a year treatment
Albendazole 400mg and ivermectin 200mcg/kg: 400 mg oral</description>
          </group>
          <group group_id="O2">
            <title>Albendazole 800mg and Ivermectin 400mcg/kg Annually</title>
            <description>Once a year treatment
Albendazole and ivermectin: albendazole 800 mg and ivermectin 400mg oral</description>
          </group>
          <group group_id="O3">
            <title>Albendazole 400mg and Ivermectin 200mcg/kg Biannually</title>
            <description>Twice a year
albendazole 400mg and ivermectin 200mcg/kg given twice a year</description>
          </group>
          <group group_id="O4">
            <title>Albendazole 800mg and Ivermectin 400mcg /kg Bi-annually</title>
            <description>Twice a year
Albendazole 800mg and ivermectin 400mcg/kg given twice a year</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Microfilarial Clearance</title>
          <description>Microfilaria clearance will be assessed in regard to dosage as well as frequency of treatment. Microfilarial clearance is defined by non-detection of microfilaria in the night blood sample.</description>
          <population>Number of participants with non detectable microfilaria at follow up</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Microfilarial Clearance at 24 Months of Follow up</title>
        <description>Microfilaria will be detected using the nucleopore filtration technique and analysed according to the respective treatment arms at the 24 month time point. Microfilarial clearance will be defined by non-detection of microfilaria in the night blood sample</description>
        <time_frame>24 months</time_frame>
        <population>Intention to treat, with last result carried forward in the case of missing visit</population>
        <group_list>
          <group group_id="O1">
            <title>Albendazole 400mg and Ivermectin 200mcg/kg Annually</title>
            <description>Once a year treatment
Albendazole 400mg and ivermectin 200mcg/kg: 400 mg oral</description>
          </group>
          <group group_id="O2">
            <title>Albendazole 800mg and Ivermectin 400mcg/kg Annually</title>
            <description>Once a year treatment
Albendazole and ivermectin: albendazole 800 mg and ivermectin 400mg oral</description>
          </group>
          <group group_id="O3">
            <title>Albendazole 400mg and Ivermectin 200mcg/kg Biannually</title>
            <description>Twice a year
albendazole 400mg and ivermectin 200mcg/kg given twice a year</description>
          </group>
          <group group_id="O4">
            <title>Albendazole 800mg and Ivermectin 400mcg /kg Bi-annually</title>
            <description>Twice a year
Albendazole 800mg and ivermectin 400mcg/kg given twice a year</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Microfilarial Clearance at 24 Months of Follow up</title>
          <description>Microfilaria will be detected using the nucleopore filtration technique and analysed according to the respective treatment arms at the 24 month time point. Microfilarial clearance will be defined by non-detection of microfilaria in the night blood sample</description>
          <population>Intention to treat, with last result carried forward in the case of missing visit</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Albendazole 400mg and Ivermectin 200mcg/kg Annually</title>
          <description>Once a year treatment
Albendazole 400mg and ivermectin 200mcg/kg: 400 mg oral</description>
        </group>
        <group group_id="E2">
          <title>Albendazole 800mg and Ivermectin 400mcg/kg Annually</title>
          <description>Once a year treatment
Albendazole and ivermectin: albendazole 800 mg and ivermectin 400mg oral</description>
        </group>
        <group group_id="E3">
          <title>Albendazole 400mg and Ivermectin 200mcg/kg Biannually</title>
          <description>Twice a year
albendazole 400mg and ivermectin 200mcg/kg given twice a year</description>
        </group>
        <group group_id="E4">
          <title>Albendazole 800mg and Ivermectin 400mcg /kg Bi-annually</title>
          <description>Twice a year
Albendazole 800mg and ivermectin 400mcg/kg given twice a year</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>joint pains</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>abdominal pains</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Neil French</name_or_title>
      <organization>University of Liverpool</organization>
      <phone>+441517959630</phone>
      <email>french@liv.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

